319 related articles for article (PubMed ID: 34301613)
1. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
[TBL] [Abstract][Full Text] [Related]
2. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
3. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
[TBL] [Abstract][Full Text] [Related]
5. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
[TBL] [Abstract][Full Text] [Related]
6. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
7. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Brown DM; Emanuelli A; Bandello F; Barranco JJE; Figueira J; Souied E; Wolf S; Gupta V; Ngah NF; Liew G; Tuli R; Tadayoni R; Dhoot D; Wang L; Bouillaud E; Wang Y; Kovacic L; Guerard N; Garweg JG
Am J Ophthalmol; 2022 Jun; 238():157-172. PubMed ID: 35038415
[TBL] [Abstract][Full Text] [Related]
8. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
9. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
[No Abstract] [Full Text] [Related]
11. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
Br J Ophthalmol; 2024 May; 108(6):852-858. PubMed ID: 37669850
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
Singh RP; Barakat MR; Ip MS; Wykoff CC; Eichenbaum DA; Joshi S; Warrow D; Sheth VS; Stefanickova J; Kim YS; He F; Cho GE; Wang Y; Emanuelli A
JAMA Ophthalmol; 2023 Dec; 141(12):1152-1160. PubMed ID: 37971723
[TBL] [Abstract][Full Text] [Related]
15. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.
Wykoff CC; Garweg JG; Regillo C; Souied E; Wolf S; Dhoot DS; Agostini HT; Chang A; Laude A; Wachtlin J; Kovacic L; Wang L; Wang Y; Bouillaud E; Brown DM
Am J Ophthalmol; 2024 Apr; 260():70-83. PubMed ID: 37460036
[TBL] [Abstract][Full Text] [Related]
16. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
17. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
[No Abstract] [Full Text] [Related]
18. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
Fukuda Y; Sakurada Y; Matsubara M; Kotoda Y; Kasai Y; Sugiyama A; Kashiwagi K
Jpn J Ophthalmol; 2023 Jul; 67(4):402-409. PubMed ID: 37289296
[TBL] [Abstract][Full Text] [Related]
19. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
20. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]